Xu Shan, Yu Yanxin, Rong Jinfeng, Hu Defeng, Zhang LiJun, Fu Shaozhi, Yang Hongru, Fan Juan, Yang Linglin, Wu Jingbo
Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, P. R. China.
Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, P. R. China.
Oncotarget. 2017 May 9;8(19):31355-31367. doi: 10.18632/oncotarget.15565.
In this study, we examined ERCC1 and BRCA1 expression and clinical outcome of 201 phase-III-IV nasopharyngeal carcinoma patients who were treated with cisplatin-based induced chemotherapy and concurrent radiochemotherapy. The chemotherapy response rate of BRCA1- and BRCA1+ patients was 73.6% and 55.8%, respectively. In addition, the chemotherapy response rate of ERCC1- and ERCC1+ patients was 76.9% and 56.6%, respectively. In patients' tissues, ERCC1 expression associated with BRCA1 expression. The chemotherapy response rate of BRCA1- and ERCC1- patients was (82.1%) and higher than that of other groups (range 52.4-73.1%). The radiochemotherapy response rate of BRCA1- and ERCC1- patients was higher than that BRCA1+ and ERCC1+ patients. BRCA1- and ERCC1- patients showed higher 3-year overall survival, failure-free survival, locoregional failure-free survival and distant failure-free survival compared to BRCA1+ or ERCC1+ patients. Moreover, the 3-year overall survival, failure-free survival and distant failure-free survival of the BRCA1- and ERCC1- group were higher than that of other groups. TNM stage, ERCC1 expression and the correlation between BRCA1 and ERCC1 expression seemed significant overall survival factors. In conclusion, in nasopharyngeal carcinoma patients, ERCC1 and BRCA1 may be a predictor of response to platinum-based chemotherapy and concurrent radiochemotherapy.
在本研究中，我们检测了201例接受以顺铂为基础的诱导化疗和同步放化疗的III-IV期鼻咽癌患者的ERCC1和BRCA1表达情况及临床结局。BRCA1阴性和阳性患者的化疗缓解率分别为73.6%和55.8%。此外，ERCC1阴性和阳性患者的化疗缓解率分别为76.9%和56.6%。在患者组织中，ERCC1表达与BRCA1表达相关。BRCA1阴性和ERCC1阴性患者的化疗缓解率为（82.1%），高于其他组（范围为52.4%-73.1%）。BRCA1阴性和ERCC1阴性患者的同步放化疗缓解率高于BRCA1阳性和ERCC1阳性患者。与BRCA1阳性或ERCC1阳性患者相比，BRCA1阴性和ERCC1阴性患者的3年总生存率、无失败生存率、局部区域无失败生存率和远处无失败生存率更高。此外，BRCA1阴性和ERCC1阴性组的3年总生存率、无失败生存率和远处无失败生存率高于其他组。TNM分期、ERCC1表达以及BRCA1与ERCC1表达之间的相关性似乎是总生存的重要因素。总之，在鼻咽癌患者中，ERCC1和BRCA1可能是铂类化疗和同步放化疗反应的预测指标。
